Clinical Trial Update: Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing romidepsin CHOP vs CHOP in untreated peripheral T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Romidepsin (romidepsin)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Peripheral T-cell Lymphoma | Phase 3 | Status: COMPLETED